Drug Type Bispecific antibody |
Synonyms PDL1/LAG-3 bispecific affimer, AVA 021, AVA-021 + [1] |
Target |
Action inhibitors |
Mechanism LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United Kingdom | - |






